APHON Chemotherapy Overview |\ |\ |\
questions with answers |\ |\
Pre-clinical Studies - CORRECT ANSWERS ✔✔purpose is to
|\ |\ |\ |\ |\ |\ |\ |\
determine safe starting dose for humans
|\ |\ |\ |\ |\
Folic Acid - CORRECT ANSWERS ✔✔Positive effect on kids w/
|\ |\ |\ |\ |\ |\ |\ |\ |\ |\
lymphoblastic leukemia |\
Clinical trials - CORRECT ANSWERS ✔✔comparing 2+ therapeutic
|\ |\ |\ |\ |\ |\ |\ |\
tx in ctl setting to evaluate effect of intervention of specific
|\ |\ |\ |\ |\ |\ |\ |\ |\ |\ |\
disease/s
Clinical Trial phase 1 - CORRECT ANSWERS ✔✔how much can you
|\ |\ |\ |\ |\ |\ |\ |\ |\ |\
handle before breakdown?
|\ |\ |\
determine max tolerated dose of drug or drug combo.
|\ |\ |\ |\ |\ |\ |\ |\
ID dose-limiting toxicities: highest dose for which incidence of
|\ |\ |\ |\ |\ |\ |\ |\ |\
dose limiting toxicities is <33%
|\ |\ |\ |\
Clinical Trial Phase 1 Patient - CORRECT ANSWERS ✔✔advanced
|\ |\ |\ |\ |\ |\ |\ |\ |\
disease, good organ function, resistant to standard therapies
|\ |\ |\ |\ |\ |\ |\
Clinical Trial phase 2 - CORRECT ANSWERS ✔✔determines
|\ |\ |\ |\ |\ |\ |\ |\
efficacy of new agent in tx of specific cancer types and validate
|\ |\ |\ |\ |\ |\ |\ |\ |\ |\ |\ |\
toxicity & dosage data. info r/t drug administration, acute
|\ |\ |\ |\ |\ |\ |\ |\ |\
toxicity, & supporting care
|\ |\ |\
, Clinical Trial phase 2 Patient - CORRECT ANSWERS ✔✔pt who
|\ |\ |\ |\ |\ |\ |\ |\ |\ |\
show little to no response to prior tx usually selected w/ normal
|\ |\ |\ |\ |\ |\ |\ |\ |\ |\ |\ |\
organ function, measurable tumor size, reasonable life
|\ |\ |\ |\ |\ |\ |\
expectancy & functional status. |\ |\ |\ |\
Includes pt who have not been treated w/ investigational drug
|\ |\ |\ |\ |\ |\ |\ |\ |\
Clinical Trial Phase 3 - CORRECT ANSWERS ✔✔determine value of
|\ |\ |\ |\ |\ |\ |\ |\ |\
agent r/t existing tx. Measure response, toxicity, survival & QOL
|\ |\ |\ |\ |\ |\ |\ |\ |\ |\
Clinical trial Phase 3 Patient - CORRECT ANSWERS ✔✔large
|\ |\ |\ |\ |\ |\ |\ |\ |\
number of newly dx who receive tx and observed over long
|\ |\ |\ |\ |\ |\ |\ |\ |\ |\ |\
period of time |\ |\
Clinical Trial Phase 4 - CORRECT ANSWERS ✔✔Occurs after agent
|\ |\ |\ |\ |\ |\ |\ |\ |\ |\
is available in commercial market. Efforts to decrease AE, toxicity
|\ |\ |\ |\ |\ |\ |\ |\ |\
w/ acceptable cure rate. Focuses more on long term safety
|\ |\ |\ |\ |\ |\ |\ |\ |\ |\
Institutional Review Board - CORRECT ANSWERS ✔✔Ensures the |\ |\ |\ |\ |\ |\ |\ |\
rights/welfare of humans are protected, by signing informed |\ |\ |\ |\ |\ |\ |\ |\
consent and requires documentation of eligibility, tx,
|\ |\ |\ |\ |\ |\ |\
modifications, toxicities, and outcome |\ |\ |\
informed consent - CORRECT ANSWERS ✔✔requires enough
|\ |\ |\ |\ |\ |\ |\
information to make decisions consistent w/ cultural, spiritual, &
|\ |\ |\ |\ |\ |\ |\ |\ |\
psychosocial values. |\ |\
purpose/duration/procedures, participant rights, possible benefits, |\ |\ |\ |\
probable risks, alternative therapies, confidentiality stmt, stmt
|\ |\ |\ |\ |\ |\ |\ |\
for voluntary participation
|\ |\
questions with answers |\ |\
Pre-clinical Studies - CORRECT ANSWERS ✔✔purpose is to
|\ |\ |\ |\ |\ |\ |\ |\
determine safe starting dose for humans
|\ |\ |\ |\ |\
Folic Acid - CORRECT ANSWERS ✔✔Positive effect on kids w/
|\ |\ |\ |\ |\ |\ |\ |\ |\ |\
lymphoblastic leukemia |\
Clinical trials - CORRECT ANSWERS ✔✔comparing 2+ therapeutic
|\ |\ |\ |\ |\ |\ |\ |\
tx in ctl setting to evaluate effect of intervention of specific
|\ |\ |\ |\ |\ |\ |\ |\ |\ |\ |\
disease/s
Clinical Trial phase 1 - CORRECT ANSWERS ✔✔how much can you
|\ |\ |\ |\ |\ |\ |\ |\ |\ |\
handle before breakdown?
|\ |\ |\
determine max tolerated dose of drug or drug combo.
|\ |\ |\ |\ |\ |\ |\ |\
ID dose-limiting toxicities: highest dose for which incidence of
|\ |\ |\ |\ |\ |\ |\ |\ |\
dose limiting toxicities is <33%
|\ |\ |\ |\
Clinical Trial Phase 1 Patient - CORRECT ANSWERS ✔✔advanced
|\ |\ |\ |\ |\ |\ |\ |\ |\
disease, good organ function, resistant to standard therapies
|\ |\ |\ |\ |\ |\ |\
Clinical Trial phase 2 - CORRECT ANSWERS ✔✔determines
|\ |\ |\ |\ |\ |\ |\ |\
efficacy of new agent in tx of specific cancer types and validate
|\ |\ |\ |\ |\ |\ |\ |\ |\ |\ |\ |\
toxicity & dosage data. info r/t drug administration, acute
|\ |\ |\ |\ |\ |\ |\ |\ |\
toxicity, & supporting care
|\ |\ |\
, Clinical Trial phase 2 Patient - CORRECT ANSWERS ✔✔pt who
|\ |\ |\ |\ |\ |\ |\ |\ |\ |\
show little to no response to prior tx usually selected w/ normal
|\ |\ |\ |\ |\ |\ |\ |\ |\ |\ |\ |\
organ function, measurable tumor size, reasonable life
|\ |\ |\ |\ |\ |\ |\
expectancy & functional status. |\ |\ |\ |\
Includes pt who have not been treated w/ investigational drug
|\ |\ |\ |\ |\ |\ |\ |\ |\
Clinical Trial Phase 3 - CORRECT ANSWERS ✔✔determine value of
|\ |\ |\ |\ |\ |\ |\ |\ |\
agent r/t existing tx. Measure response, toxicity, survival & QOL
|\ |\ |\ |\ |\ |\ |\ |\ |\ |\
Clinical trial Phase 3 Patient - CORRECT ANSWERS ✔✔large
|\ |\ |\ |\ |\ |\ |\ |\ |\
number of newly dx who receive tx and observed over long
|\ |\ |\ |\ |\ |\ |\ |\ |\ |\ |\
period of time |\ |\
Clinical Trial Phase 4 - CORRECT ANSWERS ✔✔Occurs after agent
|\ |\ |\ |\ |\ |\ |\ |\ |\ |\
is available in commercial market. Efforts to decrease AE, toxicity
|\ |\ |\ |\ |\ |\ |\ |\ |\
w/ acceptable cure rate. Focuses more on long term safety
|\ |\ |\ |\ |\ |\ |\ |\ |\ |\
Institutional Review Board - CORRECT ANSWERS ✔✔Ensures the |\ |\ |\ |\ |\ |\ |\ |\
rights/welfare of humans are protected, by signing informed |\ |\ |\ |\ |\ |\ |\ |\
consent and requires documentation of eligibility, tx,
|\ |\ |\ |\ |\ |\ |\
modifications, toxicities, and outcome |\ |\ |\
informed consent - CORRECT ANSWERS ✔✔requires enough
|\ |\ |\ |\ |\ |\ |\
information to make decisions consistent w/ cultural, spiritual, &
|\ |\ |\ |\ |\ |\ |\ |\ |\
psychosocial values. |\ |\
purpose/duration/procedures, participant rights, possible benefits, |\ |\ |\ |\
probable risks, alternative therapies, confidentiality stmt, stmt
|\ |\ |\ |\ |\ |\ |\ |\
for voluntary participation
|\ |\
